Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-10201562-B2
Application number	US-201815924028-A
Country	US
Kind code	B2
Filing date	Mar 16, 2018
Priority date	Jun 14, 2012
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A composition comprising:
a biocompatible polymer comprising:
a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, aminoethyl methacylate, aminopropyl methacylate, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and
a second monomer including an acrylate, acrylamide, a derivative thereof, or a combination thereof;
a solution with a non-physiological pH; and
a visualization agent;
wherein the biocompatible polymer is soluble in the solution and insoluble at a physiological pH at a treatment site; wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination therefore.

2. The composition of claim 1 , wherein the visualization agent is a particulate.

3. The composition of claim 1 , wherein the visualization agent has a concentration of about 5% to about 65%.

4. The composition of claim 1 , wherein the polymer is a reaction product of two different monomers.

5. The composition of claim 1 , wherein the polymer is a reaction product of three different monomers.

6. The composition of claim 1 , wherein the non-physiological pH solution is aqueous.

7. The composition of claim 1 , wherein the non-physiological pH solution is water.

8. The composition of claim 1 , wherein the non-physiological pH solution has a pH of less than about 6.

9. The composition of claim 1 , wherein the non-physiological pH solution has a pH of greater than about 8.

10. The composition of claim 1 , wherein the polymer has a concentration of about 1% w/w to about 35% w/w.

11. A composition comprising:
a first aqueous solution at non-physiological pH;
a biocompatible polymer comprising a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, aminoethyl methacylate, aminopropyl methacylate, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide, and combinations thereof; and

a second monomer including an acrylate, acrylamide, a derivative thereof, or a combination thereof;

wherein the polymer has a concentration of from about 1% to 35% w/w, that is soluble in the first aqueous solution at non-physiological pH and insoluble in a second aqueous solution at physiological pH; and
a particulate visualization agent at a concentration of from about 5% w/w to about 65% w/w; wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination therefore.

12. The composition of claim 11 , wherein the visualization agent is a particulate.

13. The composition of claim 11 , wherein the visualization agent has a concentration of about 20% to about 60%.

14. The composition of claim 11 , wherein the polymer is a reaction product of two different monomers.

15. The composition of claim 11 , wherein the polymer is a reaction product of three different monomers.

16. The composition of claim 11 , wherein the non-physiological pH solution is water.

17. The composition of claim 11 , wherein the non-physiological pH solution has a pH of less than about 6.

18. The composition of claim 11 , wherein the non-physiological pH solution has a pH of greater than about 8.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K47/30

  Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title

• A61L2430/36

  for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title